In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance

Diagn Microbiol Infect Dis. 2019 Mar;93(3):258-260. doi: 10.1016/j.diagmicrobio.2018.09.017. Epub 2018 Oct 4.

Abstract

The in vitro activity of meropenem-vaborbactam was examined against clinical carbapenem-resistant Enterobacteriaceae isolates collected over 3 years at our medical center. Only 3 KPC-producers were identified. Susceptibility to meropenem-vaborbactam was noted in 15/16 (94%) isolates (MIC90 2 mg/L) that were nonsusceptible to meropenem. Meropenem-vaborbactam may have utility at centers where non-KPC-producers are more frequent.

Keywords: Antimicrobial stewardship; CRE; KPC; Meropenem-vaborbactam.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacterial Proteins / metabolism
  • Boronic Acids / pharmacology*
  • Carbapenem-Resistant Enterobacteriaceae / drug effects*
  • Carbapenem-Resistant Enterobacteriaceae / enzymology
  • Carbapenem-Resistant Enterobacteriaceae / isolation & purification
  • Drug Combinations
  • Drug Resistance, Bacterial / drug effects*
  • Enterobacteriaceae Infections / epidemiology
  • Enterobacteriaceae Infections / microbiology*
  • Humans
  • Meropenem / pharmacology*
  • Microbial Sensitivity Tests
  • Tertiary Care Centers
  • Wisconsin / epidemiology
  • beta-Lactamase Inhibitors / pharmacology*
  • beta-Lactamases / metabolism

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Boronic Acids
  • Drug Combinations
  • beta-Lactamase Inhibitors
  • vaborbactam
  • beta-Lactamases
  • Meropenem